Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Notes Payables (2016 - 2021)

Historic Notes Payables for Adma Biologics (ADMA) over the last 6 years, with Q1 2021 value amounting to $100.0 million.

  • Adma Biologics' Notes Payables changed N/A to $100.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $100.0 million, marking a year-over-year change of. This contributed to the annual value of $100.0 million for FY2020, which is N/A changed from last year.
  • As of Q1 2021, Adma Biologics' Notes Payables stood at $100.0 million.
  • Adma Biologics' 5-year Notes Payables high stood at $100.0 million for Q4 2020, and its period low was $6.7 million during Q1 2017.
  • For the 4-year period, Adma Biologics' Notes Payables averaged around $51.2 million, with its median value being $30.0 million (2017).
  • In the last 5 years, Adma Biologics' Notes Payables surged by 5000.0% in 2017 and then changed by 0.0% in 2018.
  • Over the past 4 years, Adma Biologics' Notes Payables (Quarter) stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then surged by 233.33% to $100.0 million in 2020, then changed by 0.0% to $100.0 million in 2021.
  • Its Notes Payables was $100.0 million in Q1 2021, compared to $100.0 million in Q4 2020 and $85.0 million in Q3 2020.